Johnson Sarah K, Dennis Richard A, Barone Gary W, Lamps Laura W, Haun Randy S
Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205-7199, USA.
Mol Carcinog. 2006 Nov;45(11):814-27. doi: 10.1002/mc.20203.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by its aggressiveness and resistance to both radiation and chemotherapeutic treatment. To better understand the molecular pathogenesis of pancreatic cancer, DNA array technology was employed to identify genes differentially expressed in pancreatic tumors when compared to non-malignant pancreatic tissues. RNA isolated from 11 PDACs and 14 non-malignant bulk pancreatic duct specimens was used to probe Affymetrix U95A DNA arrays. Genes that displayed at least a fourfold differential expression were identified and real-time quantitative PCR was used to verify the differential expression of selected upregulated genes. Interrogation of the DNA array revealed that 73 genes were upregulated in PDACs and 77 genes were downregulated. The majority of the 150 genes identified have not been previously reported to be differentially expressed in pancreatic tumors, although a number of the upregulated transcripts have been reported previously. Immunohistochemistry was used to correlate calponin and insulin-like growth factor binding protein-5 (IGFBP-5) RNA levels with protein expression in PDACs and revealed peritumoral calponin staining in the reactive stroma and intense focal staining of islets cells expressing IGFBP-5 at the edge of tumors; thus implicating the interplay of various cell types to promote neoplastic cell growth within pancreatic carcinomas. As a potential modulator of cell proliferation, the overexpression of IGFBP-5 may, therefore, play a significant role in the malignant transformation of normal pancreatic epithelial cells.
胰腺导管腺癌(PDAC)的特点是具有侵袭性,并且对放疗和化疗均有抗性。为了更好地理解胰腺癌的分子发病机制,采用DNA芯片技术来鉴定与非恶性胰腺组织相比,在胰腺肿瘤中差异表达的基因。从11例胰腺导管腺癌和14例非恶性胰腺导管标本中分离出的RNA,用于探测Affymetrix U95A DNA芯片。鉴定出显示至少四倍差异表达的基因,并使用实时定量PCR来验证所选上调基因的差异表达。对DNA芯片的分析显示,73个基因在胰腺导管腺癌中上调,77个基因下调。尽管之前已经报道了一些上调的转录本,但在之前尚未报道过这150个鉴定出的基因在胰腺肿瘤中差异表达。免疫组织化学用于将钙调蛋白和胰岛素样生长因子结合蛋白-5(IGFBP-5)的RNA水平与胰腺导管腺癌中的蛋白表达相关联,结果显示在反应性基质中肿瘤周围有钙调蛋白染色,并且在肿瘤边缘表达IGFBP-5的胰岛细胞中有强烈的局灶性染色;因此提示各种细胞类型之间的相互作用促进了胰腺癌内肿瘤细胞的生长。作为细胞增殖的潜在调节因子,IGFBP-5的过表达可能因此在正常胰腺上皮细胞的恶性转化中起重要作用。